MF59-adjuvanted and virosomal influenza vaccines for preventing influenza hospitalization in older people: Comparative effectiveness using the Valencia health care information system

Puig-Barberà, Joan; Natividad-Sancho, Angels; Calabuig-Pérez, J.; Rodrigo, José Antonio Lluch; Pastor-Villalba, Eliseo; Martínez-Úbeda, Sergio; Perez‐Vilar, Silvia; Díez‐Domingo, Javier

doi:10.1016/j.vaccine.2013.05.070

Cited by 17 publications

(22 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…IVE was estimated using the widely used test-negative approach, which has been shown to give consistent results[15], and the analysis of IVE was restricted to periods with similar influenza circulation patterns[16], [35]. Furthermore, the IVE was calculated on the basis of ORs determined using a random effects model, which allowed us to take into account potential differences, including type of vaccine, vaccination programs, the levels of immunity across different population and settings, and different use of hospital emergency departments [36], [37].…”

Section: Discussionmentioning

confidence: 99%

2012-2013 Seasonal Influenza Vaccine Effectiveness against Influenza Hospitalizations: Results from the Global Influenza Hospital Surveillance Network

et al. 2014

View full text Add to dashboard Cite

BackgroundThe effectiveness of currently licensed vaccines against influenza has not been clearly established, especially among individuals at increased risk for complications from influenza. We used a test-negative approach to estimate influenza vaccine effectiveness (IVE) against hospitalization with laboratory-confirmed influenza based on data collected from the Global Influenza Hospital Surveillance Network (GIHSN).Methods and FindingsThis was a multi-center, prospective, active surveillance, hospital-based epidemiological study during the 2012–2013 influenza season. Data were collected from hospitals participating in the GIHSN, including five in Spain, five in France, and four in the Russian Federation. Influenza was confirmed by reverse transcription-polymerase chain reaction. IVE against hospitalization for laboratory-confirmed influenza was estimated for adult patients targeted for vaccination and who were swabbed within 7 days of symptom onset. The overall adjusted IVE was 33% (95% confidence interval [CI], 11% to 49%). Point estimates of IVE were 23% (95% CI, −26% to 53%) for influenza A(H1N1)pdm09, 30% (95% CI, −37% to 64%) for influenza A(H3N2), and 43% (95% CI, 17% to 60%) for influenza B/Yamagata. IVE estimates were similar in subjects <65 and ≥65 years of age (35% [95% CI, −15% to 63%] vs.31% [95% CI, 4% to 51%]). Heterogeneity in site-specific IVE estimates was high (I2 = 63.4%) for A(H1N1)pdm09 in patients ≥65 years of age. IVE estimates for influenza B/Yamagata were homogenous (I2 = 0.0%).ConclusionsThese results, which were based on data collected from the GIHSN during the 2012–2013 influenza season, showed that influenza vaccines provided low to moderate protection against hospital admission with laboratory-confirmed influenza in adults targeted for influenza vaccination. In this population, IVE estimates against A(H1N1)pdm09 were sensitive to age group and study site. Influenza vaccination was moderately effective in preventing admissions with influenza B/Yamagata for all sites and age groups.

show abstract

Section: Discussionmentioning

confidence: 99%

2012-2013 Seasonal Influenza Vaccine Effectiveness against Influenza Hospitalizations: Results from the Global Influenza Hospital Surveillance Network

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Abucasis contains an ambulatory information system called SIA, which registers any medical contact (visit), and the attending physician uses a drop-down menu with the International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) to record diagnoses. Abucasis also links other databases: Care Provision Management (GAIA), which is the drug information system available to the different professionals involved in prescription and dispensation, addressed from the Department of Health; and the Vaccine Information System (RVN) [40]. Other databases used in this study, such as the Hospital Data Surveillance System (CMBD), are described elsewhere [41] and can be linked through a unique personal identification number (SIP), for the collection of demographic data.…”

Section: Methodsmentioning

confidence: 99%

Herpes zoster surveillance using electronic databases in the Valencian Community (Spain)

et al. 2013

View full text Add to dashboard Cite

BackgroundEpidemiologic data of Herpes Zoster (HZ) disease in Spain are scarce. The objective of this study was to assess the epidemiology of HZ in the Valencian Community (Spain), using outpatient and hospital electronic health databases.MethodsData from 2007 to 2010 was collected from computerized health databases of a population of around 5 million inhabitants. Diagnoses were recorded by physicians using the International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM). A sample of medical records under different criteria was reviewed by a general practitioner, to assess the reliability of codification.ResultsThe average annual incidence of HZ was 4.60 per 1000 persons-year (PY) for all ages (95% CI: 4.57-4.63), is more frequent in women [5.32/1000PY (95% CI: 5.28-5.37)] and is strongly age-related, with a peak incidence at 70-79 years. A total of 7.16/1000 cases of HZ required hospitalization.ConclusionsElectronic health database used in the Valencian Community is a reliable electronic surveillance tool for HZ disease and will be useful to define trends in disease burden before and after HZ vaccine introduction.

show abstract

“…The MF59 oil-in-water adjuvant (Adj) emulsion enhances influenza responses in the elderly and is licensed for immunization of individuals aged 65 years and older (9)(10)(11). In infants, a first trial evaluating MF59-adjuvanted versus nonadjuvanted monovalent A/H1N1 influenza vaccines between 6 and 36 months of age showed that MF59-adjuvanted formulations generated higher response rates with persistent seroprotection (12).…”

mentioning

confidence: 99%

MF59 Mediates Its B Cell Adjuvanticity by Promoting T Follicular Helper Cells and Thus Germinal Center Responses in Adult and Early Life

Gavillet

Eberhardt

Auderset

et al. 2015

The Journal of Immunology

109

View full text Add to dashboard Cite

The early life influenza disease burden calls for more effective vaccines to protect this vulnerable population. Influenza vaccines including the MF59 oil-in-water adjuvant induce higher, broader, and more persistent Ab responses in adults and particularly in young, through yet undefined mechanisms. In this study, we show that MF59 enhances adult murine IgG responses to influenza hemagglutinin (HA) by promoting a potent T follicular helper cells (TFH) response, which directly controls the magnitude of the germinal center (GC) B cell response. Remarkably, this enhancement of TFH and GC B cells is already fully functional in 3-wk-old infant mice, which were fully protected by HA/MF59 but not HA/PBS immunization against intranasal challenge with the homologous H1N1 (A/California/7/2009) strain. In 1-wk-old neonatal mice, MF59 recruits and activates APCs, efficiently induces CD4+ effector T cells and primes for enhanced infant responses but induces few fully functional TFH cells, which are mostly follicular regulatory T cells, and poor GC and anti-HA responses. The B cell adjuvanticity of MF59 appears to be mediated by the potent induction of TFH cells which directly controls GC responses both in adult and early life, calling for studies assessing its capacity to enhance the efficacy of influenza immunization in young infants.

show abstract

MF59-adjuvanted and virosomal influenza vaccines for preventing influenza hospitalization in older people: Comparative effectiveness using the Valencia health care information system

Abstract: During the 2010-2011 influenza season, we found no differences in the risk of influenza hospitalization in subjects aged ≥65 years vaccinated with MF59-TIV compared with those vaccinated with virosomal-TIV.

Cited by 17 publications

References 26 publications

2012-2013 Seasonal Influenza Vaccine Effectiveness against Influenza Hospitalizations: Results from the Global Influenza Hospital Surveillance Network

2012-2013 Seasonal Influenza Vaccine Effectiveness against Influenza Hospitalizations: Results from the Global Influenza Hospital Surveillance Network

Herpes zoster surveillance using electronic databases in the Valencian Community (Spain)

MF59 Mediates Its B Cell Adjuvanticity by Promoting T Follicular Helper Cells and Thus Germinal Center Responses in Adult and Early Life

Contact Info

Product

Resources

About